表紙
市場調査レポート

世界のCRO市場における契約獲得戦略と事業戦略

PharmaSphere: Global Dealmaking and Operations Strategies in the CRO Market

発行 GlobalData 商品コード 284114
出版日 ページ情報 英文 125 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
世界のCRO市場における契約獲得戦略と事業戦略 PharmaSphere: Global Dealmaking and Operations Strategies in the CRO Market
出版日: 2013年09月25日 ページ情報: 英文 125 Pages
概要

医薬品開発業務受託機関(CRO)の市場は、およそ1,000社の企業がひしめく極めて細分化された市場であり、大半の企業は株式を公開していません。事業の規模も、生物学的解析を専門に行っている従業員4人の研究機関から、100以上の国々に数万人の従業員を抱える大企業まで多種多様です。

当レポートは、世界各国の50を超えるCROを取り上げ、契約獲得のための活動やインフラストラクチャ投資などを分析したもので、大小さまざまなCROがこれまでに獲得した60件以上の戦略的契約、提携や買収の動き、各地域市場の動向なども紹介し、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 CRO市場の力学

  • アウトソーシングサービスのモデル
    • 完全統合型サービスのモデル
    • 機能的サービスのモデル
    • 結論:ハイブリッドアプローチの活用
  • Quintilesの株式公開
  • 前臨床サービスの需要低迷で業務効率化に向けた動きが活発化
  • 生物製剤製造専門企業への脱皮を模索するCRO
  • 活発な投資と急成長が見込まれるアジアの新興国
  • 開発期間短縮の鍵となる臨床試験電子化技術

第4章 提携戦略と買収戦略

  • 概要
  • 合併と買収についての分析
  • 取引先である大手製薬会社との戦略的提携

第5章 各地域市場の分析

  • 概要
  • 北米市場の現状
  • 戦略的提携
  • 事業展開と世界規模でのサービス提供に向けた動き
  • 売上高の大きいCROと成長著しいCRO
  • 欧州市場の現状
  • 戦略的提携
  • 事業展開と世界規模でのサービス提供に向けた動き
  • 売上高の大きいCROと成長著しいCRO
  • アジア太平洋市場の現状
  • 戦略的提携
  • 事業展開と世界規模でのサービス提供に向けた動き
  • 売上高の大きいCROと成長著しいCRO
  • 新興国市場の現状
  • 戦略的提携
    • 中南米
    • 欧州、中東、アフリカ地域の新興国
    • 中国
    • インド
  • 事業展開と世界規模でのサービス提供に向けた動き
  • 売上高の大きいCROと成長著しいCRO

第6章 各社の経営資源活用状況

  • CRO Benchmark Reportからの抜粋
  • 経営資源の活用状況
  • 主なCROでの幹部の異動
  • 資本管理
  • 資本構成
  • 株式公開と債務再編

第7章 今後の展望

  • CRO市場
  • 各社の現状

第8章 付録

  • 調査方法
  • 執筆者について

図表

目次
Product Code: GDHC007PSR

Summary

"PharmaSphere: Global Dealmaking and Operations Strategies in the CRO Market" report covers the dealmaking activity and infrastructure investments of over 50 public and privately held contract research organizations. This report discusses and analyzes over 60 strategic deals struck by large and niche/specialty service providers. GlobalData's Industry Dynamics team evaluates the strategic drivers, fit, acquisition costs and revenue potential of these deals to illustrate the strategies different contractors are using to gain market share.

Highlights

About the Report

The report is organized into four geographies (North America, Europe, APAC and Emerging Markets) providing a drill-down analysis of each segments' revenue and growth leaders, partnership and deal activity, and operations footprint. Each region has an 'Operations and Global Service Delivery' section, which discusses how CROs are deploying their physical resources, and how they intend to use plant expansion to meet the needs of their customers. Lastly, this report provides GlobalData's outlook on the CRO sector and each company's future competitive position.

The CRO market is highly fragmented made up of some 1,000 individual companies, most of which are privately owned. These companies vary significantly in size and breadth of services - from a four-person bioanalysis research lab in Thailand to companies like Quintiles and Covance, which have tens of thousands of employees in over 100 countries across the globe. GlobalData's coverage examines these CROs through a unique company-centric lens - combining financial performance and resources allocation with partnering activity and regional developments to assess a company's overall strategy. This type of coverage is unlike any other analysis available, and delivers a consistent view into the evolution of these companies' corporate growth. We also covered some 40 other privately held CROs to give our analysis more specificity and granularity.

Key Questions Answered

  • What are the reasons for increased activity in strategic deals by leading and promising contract research organizations?
  • What drivers accounted for the revenue growth for the company over the past year?
  • Which trends will affect the CRO marketplace over the next few years?
  • What particular services or capabilities are my competitors developing?
  • Who are the revenue, and growth leaders in each region?
  • What specific business development activities are taking place, in terms of partnerships or M&A?
  • How are CROs growing their physical infrastructures and human resources to better serve the needs of their customers?
  • What region-specific operations and capabilities are CROs adding to gain share in the emerging markets?

Scope

  • This report provides analysis of the key drivers and trends shaping the global CRO market; including biologics manufacturing, emerging markets, and eClinical technologies
  • This report offers a deep dive into the synergies behind partnering and acquisition activity
  • The report contains a discussion of regional segment strategies
  • Firm utilization, resources management, and efficiency metrics
  • Leadership/Management Changes

Reasons to buy

  • Analyze and track the strategies that these CROs are using to gain share in the increasingly competitive market
  • Use this information as an independent source for your due diligence and transaction strategy
  • Organize your sales and marketing strategy to identify companies with proprietary technologies to maximize opportunities for strategic investment or partnerships
  • Understand the various factors when structuring deal terms
  • Leverage this report to identify potential take-over targets, to select vendors, or to profile CRO services/therapeutic expertise

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
    • 2.1.1. GlobalData Selection Criteria
    • 2.1.2. Companies Covered
  • 2.2. Upcoming Reports
  • 2.3. Recently Published Reports

3. CRO Market Dynamics

  • 3.1. Outsourcing Service Delivery Models
    • 3.1.1. Fully Integrated Service Model
    • 3.1.2. Functional Service Model
    • 3.1.3. The Bottom Line: Use a Hybrid Approach
  • 3.2. Quintiles Goes Public
    • 3.2.1. Quintiles IPO Raises $947M, Pricing an Increased Number of Shares at Top Range
  • 3.3. Weak Demand for Preclinical Services Causes CROs to Economize
  • 3.4. CROs are Transitioning into Becoming Experts in Biologics Manufacturing
    • 3.4.1. WuXi Will Become a Leader in Biologics Manufacturing through its Multi-pronged Strategy
    • 3.4.2. Catalent Opens New Manufacturing Center for Biologic Drug Development
    • 3.4.3. ShangPharma Inks Two mAb Partnerships
  • 3.5. Emerging Locations in Asia Will See the Greatest Investment and Growth
    • 3.5.1. Location, Location - Footprint Growth Has Become More Important than Cost Reduction
    • 3.5.2. Will Concerns about Patient Safety Bring Down the Indian Clinical Trial Market?
  • 3.6. eClinical Technologies Will be Key Drivers to Accelerating Time-to-Market
    • 3.6.1. Icon and Cerner Team Up to Streamline Late-Phase Studies
    • 3.6.2. Parexel Introduces MyTrials Platform
    • 3.6.3. INC Research Expands Partnership with Medidata Solutions
    • 3.6.4. Quintiles Unveils its Next-Generation Infosario Analytics Platform
    • 3.6.5. Covance Launches Xcellerate to Increase Clinical Trial Optimization

4. Collaboration and Acquisition Strategies

  • 4.1. Overview
  • 4.2. M&A Analysis
    • 4.2.1. KKR Makes a Splash into CRO Biz with PRA Buy
    • 4.2.2. Quintiles Invests in Personalized Medicine
    • 4.2.3. Patheon Completes Purchase of Banner Pharmacaps
    • 4.2.4. Clinipace Doubles in Size with Paragon Buyout
    • 4.2.5. Accenture Complements its R&D Service Offerings with Acquisition of Octagon
    • 4.2.6. Catalent Pharma Buys Aptuit's CTS Business
    • 4.2.7. Charles River and Covance Expand Microbial Identification Capabilities
  • 4.3. Strategic Partnerships with Large Pharmaceutical Clients
    • 4.3.1. Quintiles and Merck Serono Announce Innovative Clinical Development Partnership
    • 4.3.2. Charles River and AstraZeneca Align to Accelerate Drug Development
    • 4.3.3. Covance Deals
    • 4.3.4. Pfizer Improves Clinical Trial Flexibility with Icon and Parexel Partnership
    • 4.3.5. Aptuit and GSK Extend Strategic Alliance
    • 4.3.6. INC Research Enters into FSP Collaboration with Astellas
    • 4.3.7. PRA Announces Strategic Biosimilar Development Agreement with Amgen
    • 4.3.8. Parexel and Catalent Combine Core Competencies to Streamline Supply Chain

5. Regional Analysis

  • 5.1. Overview
  • 5.2. North America Landscape Assessment
    • 5.2.1. Pharma's Large Revenue Base in North America Continues to Drive CRO Sector Growth
  • 5.3. Strategic Partnerships
    • 5.3.1. Covance Collaborates with M2Gen and BioPontis Alliance
    • 5.3.2. AMRI Signs Agreement to License its Novel Tubulin Inhibitor Program to Chai Therapeutics
    • 5.3.3. Ockham Completes Acquisition of Nexus Oncology
    • 5.3.4. Synteract and HCR Combine to Form Multinational CRO
    • 5.3.5. Accelovance Buys Radiant's CRO Division
    • 5.3.6. Theorem Forms Relationship with IVD Consultancy Emergo Group
  • 5.4. Operations and Global Service Delivery
    • 5.4.1. AMRI Realigns its Drug Discovery Services
    • 5.4.2. PPD and Icon Grow Bioassay Capabilities in the US
  • 5.5. Revenue and Growth Leaders
    • 5.5.1. Revenue
    • 5.5.2. Revenue Growth YtY
  • 5.6. Europe Landscape Assessment
    • 5.6.1. European CRO Market Witnessed a Significant Pullback in Growth
  • 5.7. Strategic Partnerships
    • 5.7.1. TFS International Acquires Italian CRO Dimensione Ricerca
    • 5.7.2. Quintiles Signs Deal to Bring Almirall's LAMA Therapy to the UK
    • 5.7.3. Icon Selected by European Pharma Companies as a Global Strategic Partner
    • 5.7.4. CromSource Adds Early Phase Research Unit in Partnership with CRC
    • 5.7.5. Covance Inks Tech Transfer Deal with France's Inserm Transfert SA
  • 5.8. Operations and Global Service Delivery
    • 5.8.1. Patheon Invests in its SoluPath Program in the UK
    • 5.8.2. Celerion Expands Belfast Facility with Containment Room for Biologics Studies
    • 5.8.3. Harlan Labs Announces Major Investment in Switzerland
  • 5.9. Revenue and Growth Leaders
    • 5.9.1. Revenue
    • 5.9.2. Revenue Growth YtY
  • 5.10. Asia-Pacific Landscape Assessment
    • 5.10.1. APAC Market Remains Hot for Clinical Outsourcing
  • 5.11. Strategic Partnerships
    • 5.11.1. Japanese CROs Grow their Domestic Footprints
    • 5.11.2. AMRI Drives SmartSourcing Strategy in Japan
    • 5.11.3. Covance-BML Boost Clinical Trial Lab in Japan
    • 5.11.4. EPS Corporation Separates Business Units to Streamline Efficiency
    • 5.11.5. Frontage Hired by Local Chinese Clients to Develop Drugs Overseas
    • 5.11.6. DKSH Expands Services in South East Asia
  • 5.12. Operations and Global Service Delivery
    • 5.12.1. GVK BIO Selects New Distributor in Taiwan
    • 5.12.2. Max Neeman International Grows Regional Footprint
    • 5.12.3. ClinTec International
  • 5.13. Revenue and Growth Leaders
    • 5.13.1. Revenue
    • 5.13.2. Revenue Growth YtY
  • 5.14. Emerging Markets Landscape Assessment
    • 5.14.1. BRICs and Other Emerging Regions Still Represent Huge Untapped Markets for R&D
  • 5.15. Strategic Partnerships
    • 5.15.1. Central and Latin America
    • 5.15.2. Emerging EMEA
    • 5.15.3. China
    • 5.15.4. India
    • 5.15.5. Rest of Asia
  • 5.16. Operations and Global Service Delivery
    • 5.16.1. Expand Strategic Investment in Emerging Markets to Support Business Growth
  • 5.17. Revenue and Growth Leaders
    • 5.17.1. Revenue
    • 5.17.2. Revenue Growth YtY
    • 5.17.3. Global Laboratory Accreditations and Certifications

6. Firm Utilization

  • 6.1. Excerpt from CRO Benchmark Report: Heat Mapping
    • 6.1.1. Covance Was the Firm Utilization Leader in 2012
  • 6.2. Firm Utilization Metrics
    • 6.2.1. Headcount Growth YtY
    • 6.2.2. Revenue per Employee
    • 6.2.3. Clinical Services Revenue per Clinical Services Employee
    • 6.2.4. G&A Expense per G&A Employee
    • 6.2.5. S&M Expense per S&M Employee
  • 6.3. Human Capital Leadership Changes
    • 6.3.1. Source Therapeutic and Regional Expertise to Boost Clinical Operations
  • 6.4. Capital Management: Heat Map
    • 6.4.1. EPS Was the Capital Management Leader in 2012 due to its Higher Liquidity
  • 6.5. Capital Structure Metrics
    • 6.5.1. Debt/Equity Ratio
    • 6.5.2. Current Ratio
    • 6.5.3. Cash Ratio
  • 6.6. Share Offerings and Debt Restructurings
    • 6.6.1. Proceeds from Share Repurchases Used to Pay-down Debt and Finance Acquisitions

7. Future Outlook

  • 7.1. CRO Market
  • 7.2. Vendor Positioning

8. Appendix

  • 8.1. Research Methodology
    • 8.1.1. Coverage
    • 8.1.2. Secondary Research
  • 8.2. About the Author
    • 8.2.1. Adam Dion, Industry Analyst
  • 8.3. Director, Healthcare Industry Dynamics
  • 8.4. Global Head of Healthcare
  • 8.5. About the Industry Dynamics Team
  • 8.6. About GlobalData
  • 8.7. Disclosure Information
  • 8.8. Disclaimer

List of Tables

  • Table 1: Other Strategic Partnerships, North America, 2012-2013
  • Table 2: Infrastructure Investments, North America, 2012-2013
  • Table 3: Other Strategic Partnerships, Europe, 2012-2013
  • Table 4: Infrastructure Investments, Europe, 2012-2013
  • Table 5: Other Strategic Partnerships, APAC, 2012-2013
  • Table 6: Other Strategic Partnerships, Emerging Markets, 2012-2013
  • Table 7: Infrastructure Investments, Emerging Markets, 2012-2013
  • Table 8: Recent Laboratory Accreditations and Certifications, Worldwide, 2012-2013
  • Table 9: Firm Utilization Composite Scores, 2012
  • Table 10: Key Leadership Changes, 2012-2013
  • Table 11: Capital Management Composite Scores, 2012
  • Table 12: Share Offerings and Debt Restructurings , 2012-2013

List of Figures

  • Figure 1: Contract Research Organization Deals and Deal Values ($m), 2008-2012
  • Figure 2: Number of M&A Deals and Deal Values ($m), 2008-2012
  • Figure 3: Number of Licensing Deals and Deal Values ($m), 2008-2012
  • Figure 4: Combined Peer Group Revenue ($m) by Region, 2010-2012
  • Figure 5: North America Landscape Assessment, 2012
  • Figure 6: North America Revenue ($m) by Company, 2012
  • Figure 7: North America Revenue Growth by Company, 2012
  • Figure 8: Europe Landscape Assessment, 2012
  • Figure 9: Europe Revenue ($m) by Company, 2012
  • Figure 10: Europe Revenue Growth by Company, 2012
  • Figure 11: APAC Landscape Assessment, 2012
  • Figure 12: APAC Revenue ($m) by Company, 2012
  • Figure 13: APAC Revenue Growth by Company, 2012
  • Figure 14: Emerging Markets Landscape Assessment, 2012
  • Figure 15: Emerging Markets Revenue ($m) by Company, 2012
  • Figure 16: Emerging Markets Revenue Growth by Company, 2012
  • Figure 17: Headcount Growth by Company, 2012
  • Figure 18: Revenue per Employee (In $ Thousands) by Company, 2012
  • Figure 19: Clinical Srvcs Revenue per Clinical Srvcs Employee (In $ Thousands) by Company, 2012
  • Figure 20: G&A Expense per G&A Employee (In $ Thousands) by Company, 2012
  • Figure 21: S&M Expense per S&M Employee (In $ Thousands) by Company, 2012
  • Figure 22: Debt-to-Equity Ratio by Company, 4Q12
  • Figure 23: Current Ratio by Company, 4Q12
  • Figure 24: Cash Ratio by Company, 4Q12
  • Figure 25: CRO Benchmark Peer Group, Global Market Forecast, ($bn), 2012-2017
  • Figure 26: CRO Benchmark Vendor Position and 2013 Growth Projections
Back to Top